胃/胃食管连接部 (G/GEJ) 癌是一项重大的全球健康挑战。根治性手术仍然是可切除 G/GEJ 癌治疗的基石。在多项临床研究的有力证据支持下，通常建议采用辅助化疗或放化疗以及围手术期化疗等治疗方法来降低复发风险并提高术后长期生存结果。近年来，免疫检查点抑制剂（ICIs）改变了晚期或转移性 G/GEJ 癌的全身治疗格局，成为特定患者的标准一线治疗。因此，探索 ICI 在辅助或新辅助治疗可切除 G/GEJ 癌中的疗效是值得的。本综述总结了 ICI 在可切除 G/GEJ 癌中应用的最新进展。版权所有 © 2024 Lin、Chen、Huang、Ruan、Lin、Chen、Huang 和 Zhao。

Gastric/gastroesophageal junction (G/GEJ) cancer represents a significant global health challenge. Radical surgery remains the cornerstone of treatment for resectable G/GEJ cancer. Supported by robust evidence from multiple clinical studies, therapeutic approaches, including adjuvant chemotherapy or chemoradiation, and perioperative chemotherapy, are generally recommended to reduce the risk of recurrence and enhance long-term survival outcomes post-surgery. In recent years, immune checkpoint inhibitors (ICIs) have altered the landscape of systemic treatment for advanced or metastatic G/GEJ cancer, becoming the standard first-line therapy for specific patients. Consequently, exploring the efficacy of ICIs in the adjuvant or neoadjuvant setting for resectable G/GEJ cancer is worthwhile. This review summarizes the current advances in the application of ICIs for resectable G/GEJ cancer.Copyright © 2024 Lin, Chen, Huang, Ruan, Lin, Chen, Huang and Zhao.